Progress in the molecular characterization of monogenic skin disorders has been a hallmark of the past decade in investigative dermatology and has, for the first time, brought the possibility of corrective genetic therapies within reach. In addition to identification of disease genes, successful corrective gene delivery to the skin requires an understanding of disease pathogenesis, gene expression characteristics, stem cell biology, effective gene delivery, and immune modulation (Vogel, 1993; Greenhalgh et al, 1994; Krueger et al, 1994; Taichman, 1994; Khavari and Krueger, 1997; Khavari, 1997) . Because of its accessibility, the skin offers an attractive opportunity to refine gene transfer capabilities relative to current efforts underway in visceral tissues (Davis et al, 1996; Hess, 1996; Sokol and Gewirtz, 1996; Blau and Khavari, 1997) . Progress in cutaneous gene therapy, however, has lagged behind other tissues and future advances depend on rigorous studies in well-defined skin disease model systems. In this review, I focus on the current progress in therapeutic gene transfer for genetic skin disease and outline future directions in the field.
SELECTED CANDIDATE GENETIC SKIN DISEASES
The genetic basis for a number of hereditary skin diseases has been elucidated ( Table I) , with remaining uncharacterized genodermatoses currently the focus of intensive investigation. Human genetic lesions leading to skin blistering, abnormal cutaneous cornification, and cancer predisposition have been well characterized. In the epidermis, these mutations affect genes expressed selectively in either basal or suprabasal layers, as well as those expressed in both compartments. The site of such genetic defects within the epidermis can produce characteristic corresponding phenotypic abnormalities. Mutations in important basal layer genes commonly lead to skin fragility and blistering, such as is seen with laminin 5 chain gene defects in a subset of junctional epidermolysis bullosa patients (Aberdam et al, 1994; Eady and Dunnill, 1994; Pulkkinen et al, 1994; Uitto and Pulkkinen, 1996) . Suprabasal defects lead to abnormal terminal epidermal differentiation often manifested as hyperkeratosis, as seen in the case of transglutaminase 1 gene mutations in lamellar ichthyosis (Russell et al, , 1995 Huber et al, 1995a 
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disorders, especially those involving mutations in large structural proteins such as type VII collagen in dystrophic epidermolysis bullosa (Christiano et al, 1993 Hilal et al, 1993) , are likely to be intractable to small molecule pharmacotherapy and may be only effectively approached by the return of normal protein expression.
An understanding of the molecular basis of disease pathogenesis in these disorders is important in the design of rational genetic therapies. Correction of recessive disorders, in principal, requires only re-expression of the normal protein product corresponding to the previously absent or defective genes. This has been recently achieved in model efforts, as noted below (Choate et al, 1996a, b; Freiberg et al, 1997) . A greater challenge exists in the dominant disorders due to dominant-negative mutant proteins that effectively ''poison'' any wild type protein present, as in the case of keratin 1 and 10 mutants in epidermolytic hyperkeratosis (Cheng et al, 1992; Rothnagel et al, 1992) . Effective genetic correction in these latter instances requires circumventing the negative effects of such mutants in an effort to restore the function of the normal protein. Because of the considerable additional technical challenges associated with gene delivery to human somatic tissue, the recessive genetic skin disorders have been the focus of many current efforts to date.
SPECIFIC REQUIREMENTS OF GENODERMATOSES COMPARED WITH OTHER CUTANEOUS GENE TRANSFER APPLICATIONS
A recurrent theme in gene therapy efforts in all tissues is the need to tailor gene transfer approaches to specific therapeutic applications (Blau and Khavari, 1997) . In addition to genetic skin diseases, the skin is a potential tissue site for a number of distinct therapeutic gene transfer efforts and these differ considerably in their gene transfer requirements. Such potential efforts include cutaneous gene transfer for immunization (Raz et al, 1994) and for production of polypeptides for delivery to the systemic circulation (Fenjves et al, 1989; Fenjves et al, 1994) . Each of these three applications has distinctive requirements regarding efficiency of gene transfer, durability, regulation of expression of the introduced gene (the ''transgene''), and transgene immunogenicity.
High efficiency gene transfer that restores normal gene expression to all cells of a diseased tissue has been among the most challenging goals in many tissues; however, not all applications require it. Immunization via gene transfer to the skin, for example, depends on immune elements in skin and does not require uniform transgene delivery to all cells in a given tissue compartment. This may also be the case in systemic delivery of proteins expressed in skin, where the absolute magnitude of total transgene product delivered from the skin impacts the therapeutic outcome more that the percentage of cells in the skin that express it. Lasting correction of genetic skin disease, in contrast, may require high efficiency gene transfer, as could be predicted in the case of cancer prevention in patients with xeroderma pigmentosum and in the correction of cell-intrinsic structural defects such as keratin 5/14 mutations in epidermolysis bullosa simplex (Bonifas et al, 1991; Coulombe et al, 1991) . In such cases, a focal lack of corrective gene expression may be sufficient to perpetuate major elements of disease pathology (i.e., neoplastic transformation in xeroderma pigmentosum and skin fragility in epidermolysis bullosa). High efficiency genetic correction therefore may be of importance in gene therapy of genodermatoses. Gene transfer efforts in human visceral tissues have been unsuccessful in reliably sustaining therapeutic gene expression (Davis et al, 1996; Hess, 1996; Sokol and Gewirtz, 1996; Blau and Khavari, 1997) , and the ability to sustain therapeutic gene delivery for prolonged periods is another capability important in gene therapy for genetic skin disease. Whereas the need for such long-term gene delivery may be variable to nonexistent in both genetic immunization and protein delivery to the circulation from the skin, curative efforts in genodermatoses depend on lasting restoration of normal gene expression. Because this requires durable gene delivery vectors, gene targeting to long-lived skin stem cells, and avoidance of immune clearing, achieving such sustainability has proven to be a formidable challenge. Whereas periodic readminstration of therapeutic genes in the form of grafting with genetically engineered cells or by direct transfer of vectors to intact human skin tissue may be envisioned in certain lethal genetic skin disorders, achievement of sustainable cutaneous gene delivery is a major requirement for ultimate success.
The skin, by virtue of its accessibility to target gene regulation by topically applied agents, is an attractive tissue for regulated therapeutic gene production. Such regulated delivery may be of importance in the delivery of proteins to the systemic circulation, such as the hematopoietic growth factor erythropoeitin (Bohl et al, 1997) . Many of the genes affected in genetic skin disease, however, are expressed at constant levels within a given tissue compartment, as in the case of laminin 5 and keratin genes within the basal and suprabasal layers, respectively. Precise regulation of the magnitude of therapeutic gene expression in genetic skin disease may therefore be unneeded in most cases, provided gene expression may be restored to levels within a physiologic range.
The ability of a therapeutic transgene to induce a specific immune response, although central for the success of intradermal genetic immunization, represents a feared complication in gene transfer efforts for monogenic skin disease. Surprisingly, such unwanted transgene specific immune responses have not been widely reported in current gene therapy trials in other tissues, in stark contrast to inflammatory responses seen in humans with viral gene delivery vectors such as adenovirus (Knowles et al, 1995) . Because current pre-clinical models of therapeutic cutaneous gene transfer lack an intact human immune system, the extent to which unwanted immune reactions will pose a challenge may only become clear in human clinical trials. Central requirements for successful genetic correction of genetic skin disease, then, may include high efficiency genetic correction, durabilty, consistent transgene expression levels, and a lack of unwanted immune clearing of the therapeutic gene.
PROGRESS IN SPECIFIC GENODERMATOSES

Recessive ichthyoses
The ichthyotic disorders are a heterogeneous family of diseases characterized by abnormal epidermal cornification (Williams and Elias, 1987) . Recently the genetic basis for several of these disorders has been characterized (Bale and Doyle, 1994) and found to involve key enzymatic or structural proteins involved in epithelial maturation and cutaneous barrier function. Among the recessive ichthysoses are lamellar ichthyosis and X-linked recessive ichthyosis. Consistent with the nature of their gene defects in the suprabasal epidermal gene expression program, these disorders are characterized by clinical hyperkeratosis.
Lamellar ichthyosis has been associated with the TGM1 gene (Russell et al, , 1995 Huber et al, 1995a) in a subset of patients by genetic linkage and mutation analysis, and has proven to be a valuable prototype disorder for gene therapy (Choate et al, 1996a, b) due to its dramatic clinical and biochemical phenotype. The TGM1 gene encodes keratinocytes transglutaminase (TGase1) (Thacher et al, 1985; Phillips et al, 1990) , a membrane linked enzyme active in forming the cornified envelope in differentiating keratinocytes. TGase1 catalyzes the formation of isodipeptide cross-links between cornified envelope precursor molecules (Greenberg et al, 1991; Kim et al, 1995) and is believed necessary for normal terminal differentiation and barrier formation in the outer epidermis. Although not present in all lamellar ichthyosis patients Huber et al, 1995b; Parmentier et al, 1995) , TGM1 gene mutations in affected patients may produce enzymatically inactive TGase1 protein (Huber et al, 1995a) . Restoration of functional TGase1 enzymatic activity to skin from TGase1-negative patients represents a possible means of correcting this disorder.
In order to achieve this, recent work has developed an approach to achieving high efficiency transfer of the normal TGase1 gene to skin from patients characterized as TGase1-negative (Choate et al, 1996a) . This approach relies on amphotropic retroviral gene delivery vectors for the TGase1 gene (Choate et al, 1996a) . Following high efficiency gene transfer into primary patient keratinocytes grown in vitro, restoration of full length TGase1 protein expression and transglutaminase enyzmatic activity was verified. These keratinocytes were then grafted to immune deficient mice to regenerate human skin in vivo in an approach that recapitulates the histologic, gene expression, clinical, and functional features of human skin in vivo (Choate et al, 1996b; Medalie et al, 1996; Choate and Khavari, 1997a) , with the exception of immune function. Lameller ichthyosis patient keratinocytes genetically engineered with the TGase1 vector regenerated skin displaying restored TGase1 protein expression in vivo and was normalized at the levels of histology, clinical surface appearance, and barrier function; patient cells that received a control vector produced skin with the hyperkeratosis and defective skin barrier function characteristic of the disease (Choate et al, 1996b) . These findings indicated that successful phenotypic correction of human genetic skin disease tissue can be achieved via this gene transfer approach; however, this correction failed to extend beyond the 1 month timepoint after which transgene expression is commonly lost in many cutaneous gene transfer models (Gerrard et al, 1993; Taichman, 1994; Choate et al, 1996b; Fenjves et al, 1996; Choate and Khavari, 1997a; Freiberg et al, 1997) . Such loss may be due to a number of potential factors; however, in this approach it appears to be due to silencing of vector promoter elements (Choate and Khavari, 1997a) . Correction of lamellar ichthyosis patient skin tissue, then, could be achieved but not sustained.
X-linked ichthyosis is a genodermatosis that is generally much milder than lamellar ichthyosis (Williams and Elias, 1987; Paige et al, 1994) . Due to a loss of functional Arylsulfatase C (Yen et al, 1987; Shapiro et al, 1989; Alperin and Shapiro, 1994; Ballabio and Shapiro, 1995) , a steroid sulfatase believed necessary for a normal desquamation (Epstein et al, 1981) , X-linked ichthyosis constitutes another prototype recessive disorder for refinement of cutaneous gene transfer. High efficiency retroviral gene transfer followed by grafting of genetically engineered cells has also recently been used to correct X-linked ichthyosis patient skin at the level of tissue architecture, gene expression, clinical appearance, and function (Freiberg et al, 1997) . Although also not sustained for periods significantly longer than 1 month, this corrective gene transfer disease model offers another opportunity to address the challenge of durable therapeutic gene delivery to the skin.
Among the other inherited disorders of cornification are dominant disorders due to keratin mutations, such as epidermolytic hyperkeratosis (K1/K10) (Cheng et al, 1992; Rothnagel et al, 1992) , palmoplantar keratoderma subtypes (epidermolytic, K9; nonepidermolytic, K16) (Reis et al, 1994; Torchard et al, 1994; Shamsher et al, 1995) , and pachyonychia congenita subtypes (K6a/16/17) (Bowden et al, 1995; McLean et al, 1995) . In principal, these diseases represent much greater challenges to even achieving short-term correction than the recessive disorders because of the presence of proposed dominant-negative mutant keratin molecules. Additional wild type gene expression in this setting may be ineffective because such mutants can disrupt the function of normal keratin subunits in forming the intermediate filaments that give structural integrity to the cell (Freedberg, 1993; Fuchs, 1995) . A number of strategies to overcoming the challenge of dominant-negative mutants via genetic approaches are being studied, including in situ gene repair by oligonucleotide recombination and homologous gene recombination; however, none have yet been shown successful in achieving functional correction in a genodermatosis model.
Epidermolysis bullosa
The array of inherited blistering skin disorders known as epidermolysis bullosa represent prototypes of gene defects in affecting the basal epidermal program of gene expression (Eady and Dunnill, 1994; Uitto et al, 1994; Korge and Krieg, 1996; Paller, 1996; Uitto and Pulkkinen, 1996) . The recent characterization of the genes responsible for specific subtypes of this disease have revealed a corresponding heterogeneity in molecular defects (Table I) 
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A common theme emerging from these studies has been that these defects affect structural proteins, forming the vital link from the cytoplasm of basal keratinocytes through basement membrane zone components and on down into the uppermost dermis . Because of the structural nature of these proteins and the fact that many have multiple functional domains and can polymerize to form higher order structures, purely medicinal therapy has proven of little benefit. Especially in the case of more severe subtypes of epidermolysis bullosa, a key hope centers on correction of specific underlying genetic defects.
Molecular alterations in a number of specific genes responsible for epidermolysis bullosa have been increasingly well characterized over the past 5 y (Marinkovich, 1993; Uitto et al, 1994; Korge and Krieg, 1996; Paller, 1996; Uitto and Pulkkinen, 1996) . Malfunction in any of their corresponding proteins mediating epidermal adhesion, which could be envisioned to function as a series of connected links in a chain, results in skin fragility and blistering. The association of these genes with specific clinical phenotypes has shed additional light on their pathogenesis, as, for example, in the case of compound heterozygous mutations identified in the type VII collagen gene in dystrophic epidermolysis bullosa (Tamai et al, 1997) , as well as BPAG2 (McGrath et al, 1996b) and laminin 5 chains (Christiano et al, 1996; McGrath et al, 1996a) in junctional epidermolysis bullosa. The majority of genes implicated in epidermolysis bullosa are effectively produced within keratinocytes of the basal epidermal layer . This, combined with the fact that some of these genes are expressed in internal epithelia in addition to skin, underscores the fact that attempts at genetic correction in these disorders must be correctly targeted. In this regard, it is unknown whether restored expression of a basement membrane protein throughout the epidermis may result in disordered epithelial polarity, therefore it is formally possible that proteins such as laminin 5 and BPAG2 require expression limited to the basal epidermal layer. This is in contrast to corrective efforts with TGase1 and steroid sulfatase where mRNA expression throughout the epidermis via vector promoters active in all layers failed to impair their corrective impact (Choate et al, 1996b; Freiberg et al, 1997) . The fact that genetically corrected epidermolysis bullosa patient keratinocytes may have a selective adhesive advantage over uncorrected cells, however, may mitigate against these and other unanticipated potential pitfalls.
Although at an earlier stage than the ichthyoses, efforts at genetic correction of epidermolysis bullosa in model systems have focused on laminin 5 (Gagnoux-Palacios et al, 1996) and BPAG2 in junctional disease and type VII collagen in the dystrophic subtypes. It is interesting to note that revertant mosaicism in the BPAG2 gene -where a defective gene reverts to normal in a mosaic pattern in the skin -has been described in generalized benign atrophic epidermolysis bullosa, and has been noted to resemble a natural form of cutaneous gene therapy (Jonkman et al, 1997) . In the case of laminin 5, defects in one of the three chains of the laminin 5 trimer (α3, β3, or γ2) are associated with junctional epidermolysis bullosa of a severity that extends to include the severe Herlitz subtype (Aberdam et al, 1994; Pulkkinen et al, 1994; Uitto et al, 1994) . Laminin 5 γ2 chain gene transfer via both modified adenoviral and retroviral based approaches has been described in the immortalized L5 V5 keratinocyte line (Gagnoux-Palacios et al, 1996) . Such gene transfer led to restoration of normal features of laminin 5 trimer expression in a basal polarized fashion and this finding was confirmed in cysts of immortalized cells formed in vivo after subcutaneous injection into nude mice (Gagnoux-Palacios et al, 1996) . A next phase of work in genetic correction of epidermolysis bullosa will involve nontransformed tissue from patients in spatially intact epidermis.
Xeroderma pigmentosum Xeroderma pigmentosum has been associated with defects in a number of DNA repair genes and is characterized by specific inadequacies in DNA repair following ultraviolet injury (Li et al, 1993; Kraemer, 1996) . From the standpoint of gene targeting, xeroderma pigmentosum represents a pan-epidermal prototype disorder affecting both basal and suprabasal compartments, including melanocytes. The disease is characterized by photosensitivity with early onset of cutaneous neoplasias, including basal cell carcinoma, squamous cell carcinoma, and melanoma (Kraemer et al, 1990) . Much progress has been made in identifying the genes corresponding to the separate genetic complementation groups of xeroderma pigmentosum and its variants. This progress has been followed by attempts at genetic correction in xeroderma pigmentosum cells grown in tissue culture. The XPA and XPD genes have been among those best studied in this regard and their restoration to cells lacking these genes has been shown to return parameters of DNA repair and cell survival after ultraviolet injury back toward normal (Marionnet et al, 1993; Myrand et al, 1996) . While corrective gene delivery to all layers of the epithelium is readily achieved to keratinocytes by regeneration of skin using genetically engineered cells (Choate et al, 1996b; Freiberg et al, 1997) , the need to target melanocytes represents an additional formidable challenge in xerodermal pigmentosum that has not yet been systematically approached. Xeroderma pigmentosum, then, represents another serious genetic disorder in which efforts in models of genetic correction have been initiated yet in which major technical challenges remain.
REQUIRED NEW CAPABILITIES AND ALTERNATIVE APPROACHES
Widespread successful application of genetic therapies in the treatment of genetic skin disease is dependent upon the advancement of our understanding of fundamental biologic processes in the skin as well as the acquisition of new gene delivery capabilities (Fig 1) . Important biologic questions in therapeutic gene transfer involve the characterization of cutaneous stem cells and an increased understanding of cutaneous gene expression. Although impressive advances have recently been made in our understanding of the characteristics of epidermal stem cells (Jones and Watt, 1993; Rochat et al, 1994; Bata-Csorgo et al, 1995; Jones et al, 1995; Mathor et al, 1996) , no markers solely specific for these cells have yet been identified. Furthermore, our understanding of the factors controlling stem cell division and the genetic programs unique to these tissue progenitors is still in the early stages. In addition to targeting genetic elements to stem cells, long-term corrective gene delivery requires sustained transgene expression. Such expression is dependent on the gene regulatory milieu within a given tissue and, as noted above, this has not supported the achievement of long-term uniform gene expression throughout genetically engineered skin tissue by current approaches, even when vector sequences persist (Gerrard et al, 1993; Taichman, 1994; Choate et al, 1996b; Fenjves et al, 1996; Choate and Khavari, 1997a; Freiberg et al, 1997) . The factors causing this loss of transgene expression may involve mechanisms fundamental to eukaryotic gene regulation, such as promoter methylation and heterochromatin formation (Hoeben et al, 1991; Wolffe, 1992) . Recently, however, new vectors have been developed that show promise in achieving longer term gene expression in human epidermis ). An understanding of fundamental relevant biologic processes will then be important to future improvements in cutaneous gene transfer. Parallel to these advances in fundamental skin biology, new technical capabilities in gene delivery are required for sustained genetic correction of the genodermatoses. Among these are development of highly efficient vectors that can be directly administered to intact skin without unwanted immune hypersensitivity reactions. Current viral and nonviral approaches for direct gene transfer fail to meet this criteria (Hengge et al, 1995; Lu et al, 1997 ). An unsuccessful attempt to correct human lamellar ichthyosis patient skin tissue by direct TGase1 expression plasmid injection highlights some of the current challenges facing this approach to gene therapy for genodermatoses (Choate and Khavari, 1997b) . The development of new vectors and the use of immune down-modulation by blockade of costimulatory molecules such as CD28 and CD40 (Larsen et al, 1996) shows some promise in this regard. A lack of intrinsic vector stamina, however, must be addressed as well and the characterization of genetic elements conferring durable expression on therapeutic vector sequences is an important effort in achieving lasting genetic correction.
Correction of abnormal gene expression in genodermatoses may be approached by avenues distinct from transfer of the normal gene. Among such methods are oligonucleotide based repair of mutated genes by genetic recombination, direct application of recombinant proteins to affected skin, and heterologous cell therapy that circumvents immune rejection. These approaches, along with other emerging innovative strategies, may offer attractive future ways to avoid the traumatic and complicated process of grafting genetically engineered cells, which represents a current focus of models of gene therapy of genetic disease.
SUMMARY AND CONCLUSIONS
With identification of the genes involved in the pathogenesis of a number of inherited cutaneous disorders, the previously bleak prospects for patients afflicted by an array of genodermatoses may be changing for the better; however, realistic assessment of the formidable challenges remaining to routinely achieving corrective gene delivery in the skin, indicate that significant additional progress is required before this technology becomes widely applicable to these patients. Nevertheless, advances in new models of in vivo genetic correction highlight the potential promise for future successful application to patients afflicted with genetic skin disease.
